Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 313

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 313
---
 they acquire in such transactions. The purpose of such share purchases would be to increase the likelihood of obtaining stockholder approval of the Business Combination or to satisfy the closing condition in the Merger Agreement that NorthView has, in the aggregate, cash (held both in and outside of the Trust Account) that is equal to or greater than $15 million, however, such closing condition has been conditionally waived and such purchased shares would not be voted in favor of approving the Business Combination. The details of such purchases would be disclosed by NorthView in a Form 8 -KCurrent Report prior to the Special Meeting, and would be made in compliance with Rule 14e -5under the Securities Exchange Act of 1934, relying on Tender Offer Compliance and Disclosure Interpretation 166.01 (March 22, 2022). Regulatory Matters Under the HSR Act and the rules that have been promulgated thereunder by the FTC, certain transactions may not be consummated unless information has been furnished to the Antitrust Division and the FTC and certain waiting period requirements have been satisfied. The Business Combination is not subject to these requirements. At any time before or after consummation of the Business Combination, notwithstanding termination of the waiting period under the HSR Act, the applicable competition authorities the United States or any other applicable jurisdiction could take such action under applicable antitrust laws as such authority deems necessary or desirable in the public interest, including seeking to enjoin the consummation of the Business Combination, conditionally approving the Business Combination upon divestiture of Profusa’s assets, subjecting the completion of the Business Combination to regulatory conditions or seeking other remedies. Private parties may also seek to take legal action under the antitrust laws under certain circumstances. NorthView cannot assure you that the Antitrust Division, the FTC, any state attorney general, or any other government authority will not attempt to challenge the Business Combination on antitrust grounds, and, if such a challenge is made, NorthView cannot assure you as to its result. None of NorthView or Profusa are aware of any material regulatory approvals or actions that are required for completion of the Business Combination other than the expiration or early termination of the waiting period under the HSR Act. It is presently contemplated that if any such additional regulatory approvals or actions are required, those approvals or actions will be sought. There can be no assurance, however, that any additional approvals or actions will be obtained. 158 Listing of New Profusa Common Stock Approval of the listing on Nasdaq of the New